Compare ZLAB & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | STAA |
|---|---|---|
| Founded | 2013 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 867.9M |
| IPO Year | 2017 | 1995 |
| Metric | ZLAB | STAA |
|---|---|---|
| Price | $16.62 | $29.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $49.60 | $22.81 |
| AVG Volume (30 Days) | 793.9K | ★ 955.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | ★ $460,156,000.00 | $239,442,000.00 |
| Revenue This Year | $9.75 | $30.82 |
| Revenue Next Year | $26.03 | $8.41 |
| P/E Ratio | ★ N/A | $298.60 |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $15.59 |
| 52 Week High | $44.34 | $35.87 |
| Indicator | ZLAB | STAA |
|---|---|---|
| Relative Strength Index (RSI) | 31.99 | 52.62 |
| Support Level | $15.96 | $23.75 |
| Resistance Level | $19.64 | $33.86 |
| Average True Range (ATR) | 0.62 | 1.32 |
| MACD | -0.17 | -0.56 |
| Stochastic Oscillator | 8.85 | 27.10 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.